PRKAA2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL91078	0.59	20/20
SCHEMBL61677	0.57	17/20
SCHEMBL61579	0.51	17/20
SCHEMBL61866	0.51	17/20
SCHEMBL62208	0.51	14/20
Trifluoroacetic Acid (SCHEMBL63390)	0.49	14/20
SCHEMBL68693	0.47	14/20
SCHEMBL143316	0.71	13/20
SCHEMBL143624	0.70	13/20
SCHEMBL144216	0.68	13/20
SCHEMBL143534	0.67	13/20
SCHEMBL144123	0.67	13/20
SCHEMBL144150	0.64	13/20
SCHEMBL147078	0.64	13/20
SCHEMBL143522	0.64	13/20
SCHEMBL144745	0.64	13/20
SCHEMBL145930	0.62	13/20
SCHEMBL147115	0.50	13/20
Sunitinib (SCHEMBL8081)	1.00	12/20
Sunitinib (SCHEMBL8082)	1.00	12/20

Clinical trials — most relevant to PRKAA2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS)	PHASE4	RECRUITING
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer	PHASE4	WITHDRAWN
Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris	PHASE4	UNKNOWN
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients	PHASE2	COMPLETED
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals	PHASE1/PHASE2	COMPLETED
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease	PHASE2	COMPLETED
Bempedoic Acid Therapy for Polycystic Kidney Disease	PHASE2	NOT_YET_RECRUITING
Safety and Feasibility of Metformin for Sepsis Induced AKI	PHASE2	COMPLETED
The Effect of Addition of Metformin In Obese Non- Diabetic Patients With Heart Failure With Preserved Ejection Fraction	PHASE2	UNKNOWN
Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma	PHASE2	UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Metformin and Simvastatin Use in Bladder Cancer	PHASE2	UNKNOWN
Metformin for Fibromyalgia Symptoms (INFORM Trial)	PHASE2	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Effect of Age on Glucose and Lipid Metabolism	nan	COMPLETED
NASH AMPK Exercise Dosing (AMPED) Trial	nan	RECRUITING
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Influence of Intermittent Hypoxia on Glycemic Control	nan	COMPLETED
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PRKAA2 binder may also engage these)

Protein	Name	Similarity
Q8BRK8	—	1.000	Q8BRK8 →
Q5RD00	—	1.000	Q5RD00 →
Q09137	—	1.000	Q09137 →
Q28948	—	1.000	Q28948 →
P54645	—	1.000	P54645 →
Q5EG47	—	1.000	Q5EG47 →
Q5RDH5	—	1.000	Q5RDH5 →
PRKAA1	5'-AMP-activated protein kinase catalytic subunit alpha-1	1.000	landscape →
Q5R4K9	—	0.998	Q5R4K9 →
Q95ZQ4	—	0.997	Q95ZQ4 →
O19111	—	0.997	O19111 →
DCLK1	Serine/threonine-protein kinase DCLK1	0.997	landscape →
U4PR86	—	0.996	U4PR86 →
Q00372	—	0.995	Q00372 →
Q62074	—	0.995	Q62074 →
O08875	—	0.995	O08875 →
Q8BHI9	—	0.995	Q8BHI9 →
P52497	—	0.994	P52497 →
Q9NAH6	—	0.994	Q9NAH6 →
P11730	—	0.993	P11730 →
Q19266	—	0.993	Q19266 →
CAMK2D	Calcium/calmodulin-dependent protein kinase type II subunit delta	0.993	landscape →
P06782	—	0.993	P06782 →
PRKCZ	Protein kinase C zeta type	0.993	landscape →
O13945	—	0.993	O13945 →
P45894	—	0.993	P45894 →
NIM1K	Serine/threonine-protein kinase NIM1	0.993	landscape →
Q0V7M1	—	0.993	Q0V7M1 →
Q9NBK5	—	0.993	Q9NBK5 →
Q9FLZ3	—	0.993	Q9FLZ3 →